Xeris Biopharma Holdings, Inc.

Annual Trend FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025
Total Revenue $20.2m $49.3m $110.2m $163.9m $203.1m $291.8m
Cost of Goods and Service, Excluding Depreciation, Depletion, and Amortization $9.3m $13.3m $22.6m $28.6m $36.8m $42.6m
Operating expenses:
Operating Costs and Expenses $104.0m $164.7m $192.2m $207.9m $236.7m $266.9m
Operating Income (Loss) ($83.5m) ($115.2m) ($81.9m) ($44.0m) ($33.6m) $24.9m
Additional Financial Items
Amortization of Intangible Assets $0 $550k $10.8m $10.8m $10.8m $10.8m
Income (Loss) Attributable to Parent, before Tax ($91.2m) ($122.7m) ($96.1m) ($63.5m) ($57.1m) $554k
Income (Loss) from Continuing Operations before Income Taxes, Domestic $83.5m $115.2m $81.9m ($67.3m) ($78.4m) ($45.9m)
Interest Income, Other $3.0m $313k $2.6m $4.8m $5.3m $4.7m
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $83.5m $115.2m $81.9m ($63.5m) ($57.1m) $554k
Net Income (Loss) Attributable to Parent ($91.1m) ($122.7m) ($94.7m) ($62.3m) ($54.8m) $554k
Net Income (Loss) Available to Common Stockholders, Basic ($91.1m) ($122.7m) ($94.7m) ($62.3m) ($54.8m) $554k
Earnings Per Share, Basic ($2.14) ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Earnings Per Share, Diluted ($2.14) ($1.55) ($0.70) ($0.45) ($0.37) $0.00
Weighted Average Number of Shares Outstanding, Basic 79.0m 135.6m 137.7m 146.8m 160.4m
Weighted Average Number of Shares Outstanding, Diluted 79.0m 135.6m 137.7m 146.8m 172.7m
Research and Development Expense $20.9m $25.2m $21.0m $22.3m $25.6m $31.2m
Selling, General and Administrative Expense $73.7m $125.7m $137.7m $146.1m $163.5m $182.4m
Other Nonoperating Income (Expense) ($7.7m) ($7.6m) ($14.1m) ($19.5m) ($23.5m) ($24.3m)
Interest Expense (non-operating) $30.5m $29.1m
Interest Expense $10.7m $7.2m $15.3m $26.6m $30.5m $29.1m
Operating Lease, Expense $1.8m $4.5m $5.3m $5.2m
Income Tax Expense (Benefit) ($110k) $0 ($1.4m) ($1.2m) ($2.3m) $0